EyePoint Pharmaceuticals (EYPT)
(Delayed Data from NSDQ)
$9.10 USD
-0.17 (-1.83%)
Updated Jun 7, 2024 04:00 PM ET
After-Market: $9.08 -0.02 (-0.22%) 7:58 PM ET
4-Sell of 5 4
F Value F Growth F Momentum F VGM
Brokerage Reports
0 items in cart
EYEPOINT PHARMACEUTICALS, INC. [EYPT]
Reports for Purchase
Showing records 61 - 80 ( 82 total )
Company: EYEPOINT PHARMACEUTICALS, INC.
Industry: Medical - Biomedical and Genetics
ARVO 2019 Conference Highlights: Next-Generation Ophthalmology Therapeutics Emerge
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: EYEPOINT PHARMACEUTICALS, INC.
Industry: Medical - Biomedical and Genetics
1Q19 Financial Results Reported; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: EYEPOINT PHARMACEUTICALS, INC.
Industry: Medical - Biomedical and Genetics
YUTIQ 36-Month Follow-up Data Presented at ARVO 2019; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: EYEPOINT PHARMACEUTICALS, INC.
Industry: Medical - Biomedical and Genetics
Financing Completed; Reiterate Buy and Adjusting Price Target to $4.50
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: EYEPOINT PHARMACEUTICALS, INC.
Industry: Medical - Biomedical and Genetics
4Q18 Financial Results Reported; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: EYEPOINT PHARMACEUTICALS, INC.
Industry: Medical - Biomedical and Genetics
DEXYCU Commercially Launched; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: EYEPOINT PHARMACEUTICALS, INC.
Industry: Medical - Biomedical and Genetics
Debt Facility for $60M Secured to Support Product Launch; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: EYEPOINT PHARMACEUTICALS, INC.
Industry: Medical - Biomedical and Genetics
YUTIQ Commercially Launched in the U.S.; Reiterate Buy; Raising Price Target to $5
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: EYEPOINT PHARMACEUTICALS, INC.
Industry: Medical - Biomedical and Genetics
Two Product Launches This Quarter; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: EYEPOINT PHARMACEUTICALS, INC.
Industry: Medical - Biomedical and Genetics
DEXYCU Secures J-code for Reimbursement; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: EYEPOINT PHARMACEUTICALS, INC.
Industry: Medical - Biomedical and Genetics
3Q18 Financial Results Reported; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: EYEPOINT PHARMACEUTICALS, INC.
Industry: Medical - Biomedical and Genetics
YUTIQ 24-Month Data Presented in Chicago; Commercial Launch in 1Q19; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: EYEPOINT PHARMACEUTICALS, INC.
Industry: Medical - Biomedical and Genetics
Company: EYEPOINT PHARMACEUTICALS, INC.
Industry: Medical - Biomedical and Genetics
Near-Term Regulatory and Commercial Milestones; Model Adjustment; Reiterate Buy and Raising Price Target to $4.50
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: EYEPOINT PHARMACEUTICALS, INC.
Industry: Medical - Biomedical and Genetics
Fiscal 2018 Financial Results Reported; Reiterate Buy and Raising Price Target to $2.75
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: EYEPOINT PHARMACEUTICALS, INC.
Industry: Medical - Biomedical and Genetics
Pass-Through C-Code Reimbursement Secured for DEXYCU; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Company: EYEPOINT PHARMACEUTICALS, INC.
Industry: Medical - Biomedical and Genetics
Chief Financial Officer Appointed; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: EYEPOINT PHARMACEUTICALS, INC.
Industry: Medical - Biomedical and Genetics
Solid One-Year Uveitis Efficacy Data Presented; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: EYEPOINT PHARMACEUTICALS, INC.
Industry: Medical - Biomedical and Genetics
Second Tranche Financing Approved; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: EYEPOINT PHARMACEUTICALS, INC.
Industry: Medical - Biomedical and Genetics
FY2018 3Q Financial Results Reported; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R